Protease inhibitors in AIDS therapy
著者
書誌事項
Protease inhibitors in AIDS therapy
(Infectious disease and therapy series, v. 25)
Marcel Dekker, c2001
大学図書館所蔵 全3件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Details the evolution of HIV protease inhibitors from molecular development through medical applications!
Considering the latest class of revolutionary drugs fighting against HIV infection and AIDS, this comprehensive reference thoroughly examines the development and properties of HIV protease inhibitors from clinical and scientific perspectives, discussing how protease inhibitors changed the FDA approval process-enhancing the collaboration between regulatory authorities and drug developers.
Spotlights protease inhibitors as the cornerstone drugs of the first HAART regimens-key components of long-term viral suppression and immune restoration, and in secondary and tertiary regimens!
Evaluating protease inhibitors as therapeutic options and research tools, Protease Inhibitors in AIDS Therapy
reviews the impact of advances in recombinant DNA technology for understanding and treating HIV and AIDS
highlights a variety of strategies and techniques for drug discovery and development illustrated by success stories of pharmaceutical companies and biotechnology start-up firms
summarizes the pharmacokinetics, metabolism, and drug interactions of protease inhibitors
details preliminary clinical studies on oral bioavailability, pharmacokinetic profiling, efficacy, resistance, and tolerability
describes available efficacy data for marketed inhibitors and those in clinical development
reports on efforts to manage antiviral resistance in the clinic and improve patient adherence to complex drug therapy
and more!
Containing more than 600 helpful literature references, drawings, photographs, and tables, Protease Inhibitors in AIDS Therapy serves for an essential reference for infectious disease specialists, epidemiologists, virologists, immunologists, pharmacologists, medicinal chemists and biochemists, microbiologists, hematologists, hepatologists, and medical students in these disciplines.
目次
Foreword,
John G. Bartlett, The Johns Hopkins University School of Medicine, Baltimore, Maryland
HIV-1 Protease as a Target for AIDS Therapy,
John W. Erickson
Discovery and Early Development of Saquinavir,
Ian B. Duncan and Sally Redshaw
Discovery and Early Development of Ritonavir and ABT-378,
Dale J. Kemp
Discovery and Early Development of Indinavir,
Bruce D. Dorsey and Joseph P. Vacca
Discovery and Development of Nelfinavir (Viracept),
Siegfriend H. Reich
Design and Synthesis of Amprenavir, A Novel HIV Protease Inhibitor,
R. D. Tung, D. J. Livingston, B. G. Rao, E. E. Kim, C. T. Baker, J. S. Boger, S. P. Chambers, D. D. Delhinger, M. Dwyer, L. Elsayed, J. Fulghum, B. Li, M. A. Murcko, M. A. Navia, P. Novak, S. Pazhanisamy, C. Stuver, and J.A. Thomson
HIV Protease Inhibitors in Early Development,
R. Alan Chrusciel, Judith A. Nicholas, and Suvit Thaisrivongs
Pharmacology and Drug Interactions of HIV Protease Inhibitors,
Charles W. Flexner
Beneficial Pharmokinetic Interactions: Are Two Protease Inhibitors Better than One?,
Charles W. Flexner
Protease Inhibitors: Clinical Efficacy,
Roy M. Gulick
Toxicities and Adverse Effects of Protease Inhibitors,
Marshall J. Glesby
Resistance to HIV-1 Protease Inhibitors,
Benjamin Young and Daniel R. Kuritzkes
Expedited Drug Approval and HIV Protease Inhibitors,
Jeff Murray
Use of Protease Inhibitors in the Management of HIV/AIDS,
Richard C. Ogden and Charles W. Flexner
「Nielsen BookData」 より